FI95350B - Förfarande för framställning av topikalt användbart läkemedelslotion för skötsel av inflamation - Google Patents

Förfarande för framställning av topikalt användbart läkemedelslotion för skötsel av inflamation Download PDF

Info

Publication number
FI95350B
FI95350B FI895482A FI895482A FI95350B FI 95350 B FI95350 B FI 95350B FI 895482 A FI895482 A FI 895482A FI 895482 A FI895482 A FI 895482A FI 95350 B FI95350 B FI 95350B
Authority
FI
Finland
Prior art keywords
usp
weight
propylene glycol
corticosteroid
dipropionate
Prior art date
Application number
FI895482A
Other languages
English (en)
Finnish (fi)
Other versions
FI95350C (sv
FI895482A0 (sv
Inventor
Farah Joseph Munayyer
Joel August Sequeira
Rebecca Galeos
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21982389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI95350(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI895482A0 publication Critical patent/FI895482A0/sv
Application granted granted Critical
Publication of FI95350B publication Critical patent/FI95350B/sv
Publication of FI95350C publication Critical patent/FI95350C/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (10)

1. Förfarande för framställning av topiskt användbar läkeme-delslotion för skötsel av inflamationer, som innehäller 5 0,01-1,0 vikt-% godtagbar antiinlamatorisk kortikosteroid, kännetecknat därav, att kortikosteroid blandas grundligt med en vatten-alkohol-bas, som bestär av 15 - 50 vikt-% propylenglykol; 20 - 40 vikt-% isopropylalkohol; 10 20 - 60 vikt-% vatten; 0,1 - 0,5 vikt-% förtjockningsmedel, och en tillräcklig mängd buffert för att heillä blandningens pH vid 3,0 - 6,0.
2. Förfarande enligt patentkravet 1, kännetecknat 15 därav, att kortikosteroiden utgör 0,02 - 0,2 vikt-% av blandningens vikt.
3. Förfarande enligt patentkravet 1, kännetecknat därav, att kortikosteroiden är betametazon-17,21-dipropionat. 20
4. Förfarande enligt patentkravet 3, kännetecknat därav, att betametazon-17,21-dipropionat är närvarande i en mängd av 0,064 vikt-%. 25 6. Förfarande enligt patentkravet 5, kännetecknat ·* därav, att man blandar Mängd (mq/q) betametazon-dipropionat USP 0,64* 30 natriumfosfat, enbasisk, monohydrat R 2,00 fosforsyra NF ** natriumhydroxid R ** propylenglykol USP 300,00 isopropylenalkohol USP 300,00 35 hydroxipropylcellulosa NF 1,50 renat vatten USP q.s. 1,00 g * motsvarar 0,5 g betametazon/g ’· ** används för regiering av pH tili 4,5 ± 0,2. i in t di m I. 4 u : ; 95350
6. Förfarande enligt patentkravet 1, kännetecknat därav, att kortikosteroid är alkloraetazon-dipropionat.
7. Förfarande enligt patentkravet 6, kännetecknat 5 därav, att man blandar ma/g alklometasn-dipropionat USP 0,5 Carbomer 940 2,60 natriumhydroxid R 0,04 10 propylenglykol USP 200,00 isopropylenalkohol NF 300,00 klorvätesyra * renat vatten USP q.s. 1,00 g * används för regiering av pH tili 4,5. 15
8. Förfarande enligt patentkravet 1, kännetecknat därav, att kortikosteroiden är mometazon-furoat.
9. Förfarande enligt patentkravet 9, kännetecknat 20 därav, att man blandar mg/g mometason-furoat 1,0 isopropylalkolhol USP 400,0 propylenglykol USP 300,0 25 hydroxipropylcellulosa (Klucel HF) 1,5 natriumfosfat, enbasisk, monohydrat R 2,0 fosforsyra NF * renat vatten USP q.s. 1,0 g * används för regiering av pH tili 4,5 ± 0,1. 30
10. Förfarande enligt patentkravet 1, kännetecknat , : därav, att förtjockningsmedlet är akrylsyrapolymer eller hydroxipropylcellulosa. 35
FI895482A 1987-05-21 1989-11-17 Förfarande för framställning av topikalt användbart läkemedelslotion för skötsel av inflamation FI95350C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5317287 1987-05-21
US07/053,172 US4775529A (en) 1987-05-21 1987-05-21 Steroid lotion
US8801606 1988-05-20
PCT/US1988/001606 WO1988009174A1 (en) 1987-05-21 1988-05-20 Steroid lotion

Publications (3)

Publication Number Publication Date
FI895482A0 FI895482A0 (sv) 1989-11-17
FI95350B true FI95350B (sv) 1995-10-13
FI95350C FI95350C (sv) 1996-01-25

Family

ID=21982389

Family Applications (1)

Application Number Title Priority Date Filing Date
FI895482A FI95350C (sv) 1987-05-21 1989-11-17 Förfarande för framställning av topikalt användbart läkemedelslotion för skötsel av inflamation

Country Status (22)

Country Link
US (1) US4775529A (sv)
EP (2) EP0292893B2 (sv)
JP (1) JP2572124B2 (sv)
KR (2) KR930010584B1 (sv)
AT (1) ATE77745T1 (sv)
AU (1) AU616188B2 (sv)
CA (1) CA1307207C (sv)
DE (1) DE3872521T3 (sv)
DK (1) DK581989A (sv)
ES (1) ES2032898T5 (sv)
FI (1) FI95350C (sv)
GR (2) GR3005762T3 (sv)
HK (1) HK60595A (sv)
IE (1) IE60546B1 (sv)
IL (1) IL86440A (sv)
MX (1) MX9203285A (sv)
MY (1) MY103280A (sv)
NO (1) NO175762C (sv)
NZ (1) NZ224707A (sv)
PH (1) PH24528A (sv)
WO (1) WO1988009174A1 (sv)
ZA (1) ZA883566B (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942158A (en) * 1988-10-13 1990-07-17 Eastman Kodak Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol
US5241925A (en) * 1988-12-27 1993-09-07 Dermamed Apparatus and techniques for administering veterinary medicaments
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US4988500A (en) * 1989-09-29 1991-01-29 The Procter & Gamble Company Oral compositions
US5324521A (en) * 1989-12-18 1994-06-28 Dermamed Systems for transdermal administration of medicaments
US5087620A (en) * 1990-05-17 1992-02-11 Bristol-Myers Squibb Co. Controlled dermal penetration enhancement using imidazoles
KR960013445B1 (ko) * 1990-09-10 1996-10-05 쉐링 코포레이션 모메타손 푸로에이트 모노하이드레이트 및 이의 제조방법
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
KR100361240B1 (ko) * 1993-12-21 2003-01-29 쉐링 코포레이션 건선치료용약제학적조성물
DE4344697A1 (de) * 1993-12-27 1995-06-29 Beiersdorf Ag Corticosteroide enthaltende W/O-Lotion
WO1997000667A1 (en) * 1995-06-22 1997-01-09 Minnesota Mining And Manufacturing Company Stable hydroalcoholic compositions
US7566460B2 (en) * 1995-06-22 2009-07-28 3M Innovative Properties Company Stable hydroalcoholic compositions
US6623744B2 (en) 1995-06-22 2003-09-23 3M Innovative Properties Company Stable hydroalcoholic compositions
US5696105A (en) * 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
US6582711B1 (en) * 1997-01-09 2003-06-24 3M Innovative Properties Company Hydroalcoholic compositions thickened using polymers
EP0969847A1 (en) * 1997-02-20 2000-01-12 Allergan Sales, Inc. Tazarotene and corticosteroid treatment for psoriasis
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
FI974610A0 (fi) * 1997-12-23 1997-12-23 Leiras Oy Farmaceutiskt preparat i gelform
US8329758B2 (en) * 2002-02-05 2012-12-11 Gojo Industries, Inc. Skin sanitizing antimicrobial alcoholic compositions
KR20040034795A (ko) * 2002-10-17 2004-04-29 박래옥 스테로이드 제제 및 태반 추출물을 함유한 염증성 피부병치료용 경피제
EP1624861A2 (en) 2003-05-23 2006-02-15 Taro Pharmaceuticals Industries Ltd. Novel topical steroid cream formulations
WO2006130510A2 (en) 2005-05-27 2006-12-07 Taro Pharmaceuticals U.S.A., Inc. Stable liquid desoximethasone compositions with reduced oxidized impurity
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
EP1957080A4 (en) * 2005-12-09 2013-10-09 Fougera Pharmaceuticals Inc TOPICAL GLUCOCORTICOSTEROID FORMULATIONS
US20090082318A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched mometasone
EP2394653A1 (en) 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2890152A (en) * 1956-11-29 1959-06-09 Schering Corp Topical anti-inflammatory compositions
US3352752A (en) * 1963-07-25 1967-11-14 Tintex Corp Intestinal adsorbent compositions
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US3711606A (en) * 1970-09-02 1973-01-16 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active steroidal agents with dmso
DK135267A (sv) * 1971-02-25
US3758686A (en) * 1971-12-07 1973-09-11 American Cyanamid Co Method of using steroid acetonides
GB1382614A (en) * 1972-01-10 1975-02-05 Squibb & Sons Inc Steroid compositions
US3892857A (en) * 1972-11-24 1975-07-01 Squibb & Sons Inc Steroid formulation
US4013792A (en) * 1974-04-11 1977-03-22 Warner-Lambert Company Process for the production of base for topical steroids
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4070462A (en) * 1976-10-26 1978-01-24 Schering Corporation Steroid ointment
CA1163561A (en) * 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
ATE8790T1 (de) * 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
US4489070A (en) * 1983-05-13 1984-12-18 Schering Corporation Betamethasone dipropionate cream
JPS6013711A (ja) * 1983-06-21 1985-01-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− コルチコステロイドを含有する浸透局所製薬組成物
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4489071A (en) * 1983-12-09 1984-12-18 Schering Corporation Betamethasone dipropionate cream

Also Published As

Publication number Publication date
JPH02501739A (ja) 1990-06-14
EP0292893B2 (en) 1995-11-29
EP0292893B1 (en) 1992-07-01
DE3872521D1 (de) 1992-08-06
NO890271L (no) 1989-01-20
EP0362270B2 (en) 1999-11-24
IE60546B1 (en) 1994-07-27
ZA883566B (en) 1989-01-25
NO175762B (no) 1994-08-29
MX9203285A (es) 1992-07-01
DE3872521T3 (de) 2000-06-21
DK581989D0 (da) 1989-11-20
EP0362270A1 (en) 1990-04-11
KR930010584B1 (ko) 1993-10-30
MY103280A (en) 1993-05-29
ES2032898T3 (es) 1993-03-01
IL86440A (en) 1993-01-31
GR3018818T3 (en) 1996-04-30
DE3872521T2 (de) 1992-12-10
EP0362270B1 (en) 1992-07-01
AU616188B2 (en) 1991-10-24
FI95350C (sv) 1996-01-25
PH24528A (en) 1990-07-18
US4775529A (en) 1988-10-04
NZ224707A (en) 1990-09-26
GR3005762T3 (en) 1993-06-07
AU1941788A (en) 1988-12-21
DK581989A (da) 1989-11-20
CA1307207C (en) 1992-09-08
IL86440A0 (en) 1988-11-15
NO890271D0 (no) 1989-01-20
IE881517L (en) 1988-11-21
JP2572124B2 (ja) 1997-01-16
KR890701109A (ko) 1989-12-19
HK60595A (en) 1995-04-28
ES2032898T5 (es) 1996-03-01
WO1988009174A1 (en) 1988-12-01
ATE77745T1 (de) 1992-07-15
EP0292893A1 (en) 1988-11-30
NO175762C (no) 1994-12-07
FI895482A0 (sv) 1989-11-17

Similar Documents

Publication Publication Date Title
FI95350B (sv) Förfarande för framställning av topikalt användbart läkemedelslotion för skötsel av inflamation
US3711606A (en) Enhancing tissue penetration of physiologically active steroidal agents with dmso
US5422361A (en) Stable cream and lotion bases for lipophilic drug compositions
US5990100A (en) Composition and method for treatment of psoriasis
EP1051193B1 (en) Anhydrous topical skin preparation comprising ketoconazole
US8735393B2 (en) Anhydrous topical skin preparations
PT1510213E (pt) Sistemas de melhoramento de penetração e reduzida irritação incluíndo testosterona
US5236906A (en) Topical therapeutic preparation
EP0055029A2 (en) Preparations for the treatment of dermatoses
US4879274A (en) External medication for skin
US2890152A (en) Topical anti-inflammatory compositions
EP0634170B1 (en) Compositions containing 8-hydroxy-quinoline for use in the treatment of hyperproliferative skin diseases
US4915973A (en) Method for treating skin diseases
EP0244937A2 (en) Pharmaceutical compositions containing (R,S) or (S) N-(2-[2-hydroxy-3-phenoxypropyl]aminoethyl)isobutyramide
JP2003246737A (ja) 皮膚外用組成物
EP1159956B1 (en) Anhydrous topical skin preparations
US3173836A (en) Method and compositions for the treatment of cutaneous herpetic infections
EP1028731A2 (en) Stable antiandrogenic gel composition
KR930000050B1 (ko) 항균제 겔 배합물
JPH06247846A (ja) 塩酸リトドリンの経皮吸収製剤用組成物
JPH0940560A (ja) ステロイド外用剤
MXPA00004434A (en) Stable antiandrogenic gel composition
JPS60243015A (ja) 塩酸ニカルジピンの外用剤

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: SCHERING CORPORATION

MA Patent expired